ACE2-functionalized perfluorocarbon nanoemulsions block SARS-CoV-2 D614G variant and serve as oxygen carriers
Source abstract
Abstract
Abstract Severe COVID-19 is characterized by viral propagation and acute respiratory distress syndrome, often necessitating mechanical ventilation with associated complications. We designed a dual-function nanoemulsion to combat both issues simultaneously. Perfluorooctyl bromide (PFOB) nanoemulsions, stabilized by DSPE-PEG 2000 -biotin, were functionalized with recombinant human angiotensin-converting enzyme 2 (ACE2)-core streptavidin fusion proteins. These ACE2-tethered nanoparticles act as decoys, effectively binding and neutralizing SARS-CoV-2 spike protein pseudotyped lentivirus (D614G variant) in vitro , blocking infection of ACE2-expressing HEK293T cells by up to 99%. Concurrently, the high oxygen solubility of the PFOB core offers significant potential for oxygen delivery. This ACE2-anchored oxygen carrier nanoemulsion represents a promising therapeutic strategy against SARS-CoV-2 and its variants by inhibiting viral entry and mitigating hypoxia.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. 2019 novel coronavirus disease (COVID-19): paving the road for rapid detection and point-of-care diagnostics10.3390/mi11030306 ↗
2. Coronavirus envelope protein: current knowledge10.1186/s12985-019-1182-0 ↗
3. First case of 2019 novel coronavirus in the United States10.1056/NEJMoa2001191 ↗
4. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant10.1016/j.cell.2020.09.032 ↗
5. The architecture of SARS-CoV-2 transcriptome10.1016/j.cell.2020.04.011 ↗
6. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus10.1016/j.cell.2020.06.043 ↗
7. Complications of critical COVID-19: diagnostic and therapeutic considerations for the mechanically ventilated patient10.1016/j.chest.2021.10.011 ↗
8. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study10.1016/S2213-2600(20)30079-5 ↗
9. Challenges and solutions in meeting up the urgent requirement of ventilators for COVID-19 patients10.1016/j.dsx.2020.04.048 ↗
10. Complications of invasive mechanical ventilation in critically lll Covid-19 patients—a narrative review10.1016/j.amsu.2022.104201 ↗
11. Attributable mortality of ventilator-associated pneumonia among patients with COVID-1910.1164/rccm.202202-0357OC ↗
12. Bacterial ventilator-associated pneumonia in COVID-19 patients: data from the second and third waves of the pandemic10.3390/jcm11092279 ↗
13. COVID-19 ARDS: a review of imaging features and overview of mechanical ventilation and its complications10.1007/s10140-021-01976-5 ↗
14. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic10.1056/NEJMp2006141 ↗
15. Mechanical-ventilation supply and options for the COVID-19 pandemic. Leveraging all available resources for a limited resource in a crisis10.1513/AnnalsATS.202004-317CME ↗
16. Perfluorochemical-based artificial oxygen carrying red cell substitutes10.1016/0955-3886(94)00067-t ↗
17. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The liquivent study group10.1056/NEJM199609123351101 ↗
18. Perfluorinated blood substitutes and artificial oxygen carriers10.1054/blre.1999.0113 ↗
19. Current status of artificial oxygen carriers10.1016/s0169-409x(99)00046-0 ↗
20. Perfluorohexane attenuates proinflammatory and procoagulatory response of activated monocytes and alveolar macrophages10.1097/00000542-200101000-00020 ↗
21. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems10.1097/01.PCC.0000059729.21375.D0 ↗
22. Differential impact of perfluorochemical physical properties on the physiologic, histologic, and inflammatory profile in acute lung injury10.1097/01.ccm.0000163218.79770.29 ↗
23. Pulmonary applications of perfluorochemical liquids: ventilation and beyond10.1016/j.prrv.2005.03.010 ↗
24. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery10.1081/bio-200046659 ↗
25. Partial liquid ventilation-induced mild hypothermia improves the lung function and alleviates the inflammatory response during acute respiratory distress syndrome in canines10.1016/j.biopha.2019.109344 ↗
26. Blood substitutes and oxygen therapeutics: a review10.1213/ANE.0000000000003957 ↗
27. Acute lung injury: outcomes and new therapies10.1053/prrv.2000.0097 ↗
28. Fluorocarbons facilitate lung recruitment10.1007/s00134-003-1881-1 ↗
29. Partial liquid ventilation in adult patients with acute respiratory distress syndrome10.1164/rccm.200508-1196OC ↗
30. Inactivation of SARS-CoV-2 spike protein pseudotyped virus infection using ACE2-tethered gold nanorods under near-infrared laser irradiation10.1021/acsanm.2c04275 ↗
31. Rapid concentration and purification of retrovirus by flocculation with Polybrene10.1016/j.jbiotec.2006.03.026 ↗
32. Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half-lives and sensitivity10.1002/nbm.3059 ↗
33. Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?10.21037/atm.2017.09.17 ↗
34. Dispersion method for safety research on manufactured nanomaterials10.2486/indhealth.2012-0218 ↗
35. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo10.1038/s42003-023-04860-9 ↗